Q1 Earnings Estimate for BEAM Issued By HC Wainwright

Beam Therapeutics Inc. (NASDAQ:BEAM) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for shares of Beam Therapeutics in a research report issued to clients and investors on Monday, February 3rd. HC Wainwright analyst P. Trucchio anticipates that the company will earn ($0.83) per share for the quarter. HC Wainwright has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.81) EPS and FY2029 earnings at ($1.44) EPS.

Beam Therapeutics (NASDAQ:BEAM) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.01). The firm had revenue of $14.30 million for the quarter, compared to analysts’ expectations of $14.52 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The company’s revenue for the quarter was down 16.9% on a year-over-year basis. During the same period in the prior year, the company earned ($1.22) earnings per share.

BEAM has been the topic of a number of other reports. Leerink Partners upgraded Beam Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $27.00 to $39.00 in a research note on Wednesday, November 6th. Royal Bank of Canada decreased their target price on shares of Beam Therapeutics from $27.00 to $24.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 6th. Wedbush reiterated an “outperform” rating and issued a $57.00 price target on shares of Beam Therapeutics in a report on Monday, January 13th. Cantor Fitzgerald upgraded shares of Beam Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Wednesday, January 29th. Finally, Leerink Partnrs upgraded shares of Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $47.67.

Beam Therapeutics Trading Up 8.0 %

Shares of BEAM opened at $27.82 on Tuesday. The stock’s 50 day moving average is $26.49 and its two-hundred day moving average is $25.77. Beam Therapeutics has a twelve month low of $20.84 and a twelve month high of $49.50. The firm has a market capitalization of $2.30 billion, a PE ratio of -15.81 and a beta of 1.92.

Institutional Trading of Beam Therapeutics

Hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Beam Therapeutics by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,981 shares of the company’s stock worth $75,000 after purchasing an additional 524 shares during the period. Blue Trust Inc. increased its stake in Beam Therapeutics by 84.0% in the third quarter. Blue Trust Inc. now owns 3,135 shares of the company’s stock valued at $73,000 after purchasing an additional 1,431 shares during the last quarter. Arcadia Investment Management Corp MI purchased a new position in Beam Therapeutics during the third quarter worth about $98,000. KBC Group NV boosted its stake in Beam Therapeutics by 103.2% in the 4th quarter. KBC Group NV now owns 4,143 shares of the company’s stock worth $103,000 after buying an additional 2,104 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in Beam Therapeutics by 13.3% in the 3rd quarter. GAMMA Investing LLC now owns 4,620 shares of the company’s stock valued at $113,000 after buying an additional 544 shares during the period. Institutional investors and hedge funds own 99.68% of the company’s stock.

Insider Buying and Selling at Beam Therapeutics

In related news, insider Christine Bellon sold 1,241 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the transaction, the insider now owns 102,968 shares of the company’s stock, valued at approximately $2,541,250.24. The trade was a 1.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO John M. Evans sold 30,000 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $26.75, for a total transaction of $802,500.00. Following the completion of the transaction, the chief executive officer now owns 908,659 shares in the company, valued at approximately $24,306,628.25. This trade represents a 3.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.20% of the company’s stock.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.